FierceBiotech1h
GSK drops one potential ‘functional cure’ for hep B as it goes all-in on bepirovirsen
GSK is prioritizing development of its hepatitis B treatment bepirovirsen, as the pharma ends work on another potential ...
GlaxoSmithKline (GSK) Gets a Sell from J.P. Morgan
In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...
GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After Beating Market Views
The pharmaceutical company citied promising pipeline developments and said cancer treatments drove above-expected growth.
GSK Announces £2 Billion Share Buyback as Profit Beats Estimates
GSK Plc announced a share buyback of £2 billion as it saw better than expected profit in the fourth quarter. The share ...
GSK launches £2bn buyback on strong HIV and cancer drugs sales
GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines including cancer and HIV drugs, sending shares up as much as 6 per cent on ...
GSK lifts 2031 sales target after better-than-expected Q4
GSK posted a better-than-expected fourth quarter on Wednesday and lifted its 2031 sales target to nearly $50 billion as the ...
GSK shares leap 5% as results top forecasts and guidance is upgraded! Can they keep rising?
Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains. The post ...
GSK falls Tuesday, underperforms market
GSK PLC closed 24.32% short of its 52-week high of £18.24, which the company achieved on May 16th.
bovnews17h
GSK’s Unexpected Plunge: What’s Next?
On Monday, GSK plc (GSK) stock saw a decline, ending the day at $34.9 which represents a decrease of $-0.37 or -1.05% from the prior close of $35.27. The stock opened at $34.87 and touched a low of ...